Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2545-2552

  Perez Manga G ^a   Lluch, A ^a   Alba, E ^a   Moreno Nogueira, J A ^a   Palomero, M ^a   Garcia Conde J ^a   Khayat, D ^a   Rivelles, N ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0342647532     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2545     Document Type: Article

References (32)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
2. Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994
3. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active agent in previously untreated extensive small cell lung cancer (SCLC): A study of the National Cancer Institute of Canada Clinical Trial Group. Ann Oncol 5:283-285, 1994
4. Anderson H, Lund B, Bach F, et al: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
5. Gatzemeier U, Shepherd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 32A:243-248, 1996
6. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
7. Carmichael J, Fink U, Russell RCG, et al: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73:101-105, 1996
8. Carmichael J, Possinger K, Phillip P, et al: Advanced breast cancer. A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995
9. Carmichael J, Walling J: Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol 23:77-81, 1996 (suppl 10)
10. Tonato M, Mosconi AM, Martin C: Safety profile of gemcitabine. Anticancer Drugs 6:27-32, 1995 (suppl 6)
11. Green MR: Gemcitabine safety overview. Semin Oncol 23:32-35, 1996 (suppl 10)
12. Possinger K: Gemcitabine in advanced breast cancer. Anticancer Drugs 6:55-59, 1995 (suppl 6)
13. Blackstein M, Vogel CL, Ambinder R, et al: Phase II study of gemcitabine in patients with metastatic breast cancer. Eur J Cancer 33:S149, 1997 (abstr)
14. Spielmann M, Pouillart P, Espie M, et al: Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracydine-containing regimens. Eur J Cancer 33: S149, 1997 (abstr)
15. Brown T, O'Rourke T, Burris H, et al: A phase I trial of gemcitabine LY188011 administered iv every two weeks. Proc Am Soc Clin Oncol 10:115, 1991 (abstr)
16. Le Chevalier T, Gottfried M, Gatzemeier U, et al: Confirmatory activity of gemcitabine in non-small cell lung cancer. Eur J Cancer 29:S160, 1993 (suppl 16) (abstr)
17. Mross K, Maessen P, van der Vijgh WJF, et al: Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6:517-526, 1988
18. Speth PAJ, van Hoesel QGCM, Hannen C: Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15-31, 1988
19. Rushing DA, Piscitelli SC, Rodvold KA, et al: The disposition of doxorubicin on repeated dosing. J Clin Pharmacol 33:698-702, 1993
20. O'Brien MER, Talbot DC, Smith IE: Carboplatin in the treatment of advanced breast cancer: A phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 11:2112-2117, 1993
21. Andersson M, Daugaard S, Von der Masse H, et al: Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: A randomised study. Cancer Treat Rev 70:1181-1186, 1986
22. Jones WG: Effective palliation of advanced breast cancer with weekly low dose epirubicin. Eur J Cancer Clin Oncol 25:357-360, 1989
23. Mross K, Bohn C, Edler L, et al: Randomized phase II study of single-agent epirubicin ± verapamil in patients with advanced metastatic breast cancer: An AIO Clinical Trial - Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society. Ann Oncol 4:45-50, 1993
24. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993
25. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
26. Klaassen U, Diergarten K, Ditrich CH, et al: Randomised trial of 2 doses of Taxol in metastatic breast cancer: An interim analysis. Oncologie 17:86-90, 1994
27. Seidman AD, Reichman BS, Crown T-J, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
28. Sledge GW Jr, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997 (abstr 2)
29. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 388)
30. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac-effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
31. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993 (suppl 3)
32. Moursiden H: Systematic therapy of advanced disease. Drugs 44:17-28, 1992